Peptide record

TPDB92088

BLP-7 Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92088
BLP-7
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP Antifungipept CAFPdb ToxinPred 3.0
modified_plain
Yes
A 27-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIGGALLSAGKSALKGLAKGLAEHFAN-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
27 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Bombina orientali Activity
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.61 µM
Anticancer
0.61 µM

Target

Liver Cancer
SK-HEP-1
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 2.83 µM
Anticancer
2.83 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 1.81 µM
Anticancer
1.81 µM

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 4 Activity

Activity

Cell Viability
Cell Viability ~ 20% at 2.5 µM
Anticancer
~20 % at 2.5 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 5 Activity

Activity

Cell Viability
Cell Viability ~ 20% at 2.5 µM
Anticancer
~20 % at 2.5 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 6 Activity

Activity

Cell Viability
Cell Viability < 20% at 10 µM
Anticancer
<20 % at 10 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018